Atherosclerosis calcification: focus on lipoproteins

JG Neels, G Leftheriotis, G Chinetti - Metabolites, 2023 - mdpi.com
Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of
lipids in the vessel wall, leading to the formation of an atheroma and eventually to the …

Vascular calcification: from the perspective of crosstalk

S Yang, Z Zeng, Q Yuan, Q Chen, Z Wang, H Xie… - Molecular …, 2023 - Springer
Vascular calcification (VC) is highly correlated with cardiovascular disease morbidity and
mortality, but anti-VC treatment remains an area to be tackled due to the ill-defined …

Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study

M Ruscica, C Macchi, A Giuliani, AS Rizzuto… - Cardiovascular …, 2023 - Springer
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of
morbidity and mortality, being twofold to fourfold more common in patients with type 2 …

PCSK9 confers inflammatory properties to extracellular vesicles released by vascular smooth muscle cells

MF Greco, AS Rizzuto, M Zarà, M Cafora… - International journal of …, 2022 - mdpi.com
Vascular smooth muscle cells (VSMCs) are key participants in both early-and late-stage
atherosclerosis and influence neighbouring cells possibly by means of bioactive molecules …

Impact of PCSK9 inhibition on proinflammatory cytokines and matrix metalloproteinases release in patients with mixed hyperlipidemia and vulnerable atherosclerotic …

M Basiak, M Kosowski, M Hachula, B Okopien - Pharmaceuticals, 2022 - mdpi.com
Atherosclerosis is a disorder in which, in addition to high cholesterol levels, several plasma
factors play a significant role in its development. Among these cytokines and molecules are …

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia

H Jiang, L Li, X Zhang, J He, C Chen… - Journal of Cachexia …, 2024 - Wiley Online Library
Background The effects of lipid‐lowering drugs [including statins, ezetimibe, and proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors] on hyperlipidaemia have been …

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease

BE Suur, M Chemaly, M Lindquist Liljeqvist… - Frontiers in …, 2022 - frontiersin.org
Proprotein convertase subtilisin/kexins (PCSKs) constitute a family of nine related proteases:
PCSK1-7, MBTPS1, and PCSK9. Apart from PCSK9, little is known about PCSKs in …

Impact of alirocumab on release markers of atherosclerotic plaque vulnerability in patients with mixed hyperlipidemia and vulnerable atherosclerotic plaque

M Kosowski, M Basiak, M Hachuła, B Okopień - Medicina, 2022 - mdpi.com
Background and Objectives: Atherosclerosis is a disease in the pathogenesis of which
plasma factors apart from elevated cholesterol levels play a keyrole. Such factors include …

Fibroblasts' secretome from calcified and non-calcified dermis in Pseudoxanthoma elasticum differently contributes to elastin calcification

FD Lofaro, S Costa, ML Simone, D Quaglino… - Communications …, 2024 - nature.com
Pseudoxanthoma elasticum (PXE) is a rare disease characterized by ectopic calcification,
however, despite the widely spread effect of pro/anti-calcifying systemic factors associated …

Regulation of cardiovascular calcification by lipids and lipoproteins

JJ Hsu, Y Tintut, LL Demer - Current opinion in lipidology, 2022 - journals.lww.com
Regulation of cardiovascular calcification by lipids and lip... : Current Opinion in Lipidology
Regulation of cardiovascular calcification by lipids and lipoproteins : Current Opinion in …